Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Đánh giá kinh tế của yếu tố kích thích tạo bạch cầu hạt
Tóm tắt
Sự không chắc chắn phổ biến về vị thế kinh tế dược phẩm của yếu tố kích thích tạo bạch cầu hạt (G-CSF) trong việc phòng ngừa và điều trị giảm bạch cầu trung tính do hóa trị đã dẫn đến một số đánh giá kinh tế dược phẩm được công bố trong vòng 10 năm qua. Các nghiên cứu này khác nhau đáng kể về các phương pháp được sử dụng và các kết quả được trình bày. Để đóng góp vào việc làm rõ vị thế kinh tế dược phẩm của G-CSF, một đánh giá hệ thống về các đánh giá kinh tế đã được tiến hành. Trọng tâm của đánh giá là phòng ngừa và điều trị giảm bạch cầu do hóa trị ở bệnh nhân mắc ung thư. Một tìm kiếm thư mục máy tính trên một số cơ sở dữ liệu đã được thực hiện, yielding 33 nghiên cứu. Các phát hiện cho thấy tiềm năng tiết kiệm chi phí của G-CSF trong hóa trị liều tiêu chuẩn là hạn chế, với chi phí thấp hơn thường thấy trong nhóm đối chứng. Kết quả của các nghiên cứu này quá khác biệt để rút ra một khuyến nghị rõ ràng từ góc độ tiết kiệm chi phí. Việc quản lý G-CSF sau hóa trị liều cao với hỗ trợ tế bào gốc thường dẫn đến tiết kiệm chi phí hơn trong nhóm G-CSF so với hóa trị liều tiêu chuẩn, minh họa cho một tiềm năng tiết kiệm chi phí khả thi của G-CSF. Trong điều trị giảm bạch cầu trung tính cấp sốt do hóa trị đã thiết lập, tiết kiệm chi phí được tìm thấy trong tất cả các nghiên cứu. Kết quả này thật bất ngờ nhưng bị hạn chế bởi số lượng nghiên cứu nhỏ (n = 5) và vẫn cần được xác nhận bởi các phân tích kinh tế prospectively được thiết kế nghiêm ngặt hơn. Mặc dù có nhiều nghiên cứu đáng kể về chủ đề này, đánh giá kinh tế của G-CSF còn xa mới được giải quyết và cần thêm nhiều điều tra hơn.
Từ khóa
#G-CSF #đánh giá kinh tế #giảm bạch cầu trung tính #hóa trị.Tài liệu tham khảo
Hollingshead LM, Goa KL. Recombinant granulocyte-colony stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991 Aug; 42 (2): 300–30
Adams JR, Lyman GH, Djubegovic B, et al. G-CSF as prophy-laxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 2002; 3 (9): 1273–81
Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998 Sep; 16 (9): 3179–90
Bennett CL, Smith TJ, Hillner BE, et al. Free-riding and prisoner’s dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 1995 Sep 13; 14 (9): 2457–63
Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. J Clin Oncol 1996 Sep; (14): 2511–20
Frampton JE, Faulds D. Filgrastim: a reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 1996 Jan; 9 (1): 76–96
Dickersin K, Scherer R, Levebvre C. Identifying relevant studies for systematic reviews. BMJ 1994 Nov 12; 309 (6964): 1286–91
Kraemer HC, Andrews G. A nonparametric technique for metaanalysis effect size calculation. Psychol Bull 1982; 91 (2): 404–12
Bennett CL, Stinson TJ, Lane D, et al. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol 2000 Feb; 34 (2): 92–6
Chouaid C, Bassinet L, Fuhrmann C, et al. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998 Aug; 16 (8): 2700–7
Dranitsaris G, Sutcliffe SB. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin’s and non-Hodgkin’s lymphoma. Leuk Lymphoma 1995 Mar; 17 (1–2): 139–45
Dranitsaris G, Altmayer C, Quirt I. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin’s lymphoma. Pharmacoeconomics 1997 Jun; 11 (6): 566–77
Glaspy JA, Bleeker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Fur J Cancer 1993; 29A Suppl. 7: 23–30
Le Du I, Lebert P, Le Corre P, et al. Étude pharmaco-économique du G-CSF dans le treaement des lymphomes malins non hodgkiniens. J Pharm Clin 1996 Jun; 15 (2): 113–7
Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoetic growth factor use in patients receiving cancer chemotherapy. J Nall Cancer Inst 1993 Mar 17; 85 (6): 488–93
Messori A, Trippoli S, Tendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: metaanalysis and pharmacoeconomic evaluation. J Clin Pharm Ther 1996 Apr; 21 (2): 57–63
Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994 Jun; 12 (6): 1245–50
Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lympoblastic leukemia. N Engl J Med 1997 Jun 19; 336 (25): 1781–7
Riikonen P, Rahalia J, Salonvaara M, et al. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995 May; 13 (3): 289–94
Rubino C, Laplanche C, Patte C, et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after introduction chemotherapy in children with non-Hodgkin’s lymphoma. J Nall Cancer Inst 1998 May; 90 (10): 750–5
Schröder CP, de Vries EG, Mulder NH, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocytecolony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother 1999 May; 43 (5): 741–3
Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin’s lymphoma treated with combination chemotherapy. Ann Oncol 1994; 5 Suppl. 2: 127–32
Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991 Jul; 325 (3): 164–70
Brice P, Godin S, Libert O, et al. Influence du facteur de croissance granulocytaire sur le coût des autogreffes de moelle en onco-hématologie. Presse Med 1994 Oct; 23 (33): 1512–5
Clark RE, Shlebak AA, Creagh MD. Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leuk Lymphoma 1994 Dec; 16 (1–2): 141–6
Duncan N, Hewetson M, Atra A, et al. An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children. Pharmacoeconomics 1997 Feb; 11 (2): 169–4
Kucharski AJ, Ghalie R, Greenstein S, et al. The clinical effectiveness and financial impact of utilizing peripheral blood progenitor cells as rescue therapy following autologous bone marrow transplant. Int J Technol Assess Health Care 1996; 12 (1): 172–9
Lee SJ, Weller E, Alyea EP, et al. Efficacy and costs of granulocyte colony-stimulating factor in allogenic T-cell de-pleted bone marrow transplantation. Blood 1998 Oct 15; 92 (8): 2725–9
Souêtre E, Quing W, Pénelaud PF. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Fur J Cancer 1996; 32A (7): 1162–5
Uyl-de Groot CA, Richel DJ, Rutten FF. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Fur J Cancer 1994; 30A (11): 1631–5
Dunlop DJ, Fitzsimons EJ, McMurray A, et al. Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1994 Nov; 70 (5): 943–5
Lee SM, Radford JA, Dobson L, et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin’s lymphoma: clinical bene-fits at no extra cost. Br J Cancer 1998 Apr; 77 (8): 1294–9
McQuaker IG, Hunter AE, Pacey S, et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997 Feb; 15 (2): 451–7
Ojeda E, Garcia-Bustos J, Aguado M, et al. A prospective randomized trial of granulocyte colony-stimulating factor ther-apy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999 Sep; 24 (6): 601–7
Stinson TJ, Adams JR, Bishop MR, et al. Economic analysis of a phase III study of G-CSF vs placebo following stem cell transplantation. Bone Marrow Transplant 2000 Sep; 26 (6): 663–6
Tarella C, Castellino C, Locatzelli F, et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical ben efits and reduction of treatment costs. Bone Marrow Transplant 1998 Feb; 21 (4): 401–7
Viens P, Genre D, Protière C, et al. Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer. Fur Cytokine Netw 1998 Mar; 9 (1): 93–8
Flynn TN, Kelsey SM, Hazel DL, et al. Cost effectiveness of amphotericin B plus G-CSF compared to amphotericin mono-therapy: treatment of presumed deep fungal infection in neu tropenic patients in the UK. Pharmacoeconomics 1999 Nov; 16 (5 Pt 2): 543–50
García-Carbonero R, Mayordomo JI, Tomamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high risk febrile neutropenia: a multicenter randomized trial. J Nall Cancer Inst 2001 Jan; 93 (1): 31–8
Mateos RJ, Gonzáles JB, Lloret CA, et al. Aproximación a un analysis coste-efectividad del tratamiento con G-CSF en tumores no sólidos. Farm Clin 1994 Mar; 11 (2): 122–34
Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony stimulating factors. J Nall Cancer Inst 1995 Jun; 87 (11): 803–8
Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997 Mar; 15 (3): 1163–70
Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996 Aug; 313 (7052): 275–83
Lyman GH, Kuderer NM, Djubegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002 Apr; 112 (5): 406–11
Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62 Suppl. 1: 1–15
American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence based clinical practice guidelines. J Clin Oncol 2000 Oct; 18 (20): 3558–85
Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematological malignancies and solid tumors. J Clin Oncol 1997 Aug; 15 (8): 2981–95
Lyman GH, Kuderer N, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Fur J Cancer 1998 Nov; 34 (12): 1857–64
Standaert B, Goldstone J, Lu J, et al. Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data. Pharmacoeconomics 2002; 20 (10): 665–74
Bessmertny O, Cairo MS. Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay? J Pediatr Hematol Oncol 2003 Jun; 25 (6): 435–40
Silber III, Fridman M, Shpilsky A, et al. Modeling the cost-effectiveness of granulocyte-colony stimulating factor in early-stage breast cancer. J Clin Oncol 1998 Jul; 16 (7): 2435–44
Balducci L, Hardy CL, Lyman GH. Hematopoietic growth factors in the older cancer patients. Curr Opin Hematol 2001 May; 8 (3): 170–87
Lyman GH. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. Fur J Cancer 2000 Apr; 36 Suppl. 1: 15–21
Faucher C, Corroller AG, Blaise D, et al. Comparison of GCSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994 Dec; 14 (6): 895–901
de Azevedo AM, Nucci M, Maiolino A, et al. A randomized multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002 May; 29 (9): 745–51
Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer 2002 Apr; 10 (3): 181–8
Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a doubleblind, placebo-controlled trial. Ann Intern Med 1994 Oct; 121 (7): 492–501
Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997 Jun; 336 (25): 1776–80